Molecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR): Cardiac Sarcoidosis
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Edinburgh
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Myocardial 18F-FDG uptake
Study Overview
Brief Summary
PET scanning (positron emission tomography) is a well-established technique used to identify areas of interest within the body. It involves injecting a radioactive tracer which highlights abnormal areas. It has recently been combined with CT (computed tomography) and MRI (magnetic resonance imaging) scanning to more accurately identify abnormalities within the heart. Cardiac sarcoidosis, a condition which causes scarring and inflammation within the heart muscle, is of particular interest.
The study makes use of hybrid PET/MR scanning using a designated scanner which enables PET scanning combined with MRI scanning. This will allow imaging of abnormal areas within the heart in this condition alongside treatment regimens in a way which hasn't been done before. If successful, this imaging method will play a key role in diagnosing, quantifying and monitoring these conditions.
All participants will undergo PET scanning, where a radioactive tracer is injected into a vein before the scan. The radioactive substance only lasts for a short time and is safe, passed out of the body in urine. The scan will be performed twice; once before treatment and once after treatment has been established. A cohort of healthy volunteers will undergo scanning in exactly the same way to enable us to compare the results with hearts of people who don't have cardiac sarcoidosis.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Cardiac Sarcoidosis Patients:
- •Aged over 40 years
- •Completion of informed consent
- •Established diagnosis of cardiac sarcoidosis
- •Established diagnosis as per HRS recommended diagnostic criteria
- •Healthy Volunteers:
- •Aged over 40
- •Completion of informed consent
Exclusion Criteria
- •All participants:
- •Inability or unwilling to give informed consent
- •Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial.
- •Major intercurrent illness with life-expectancy <2 years.
- •Renal dysfunction (eGFR less than or equal to 30ml/min/1.73m2)
- •Adverse reaction or hypersensitivity to 18F-FDG PET tracer
- •NYHA Class IV heart failure
- •Patients with atrial fibrillation and poor rate control
- •Contraindications to MRI scanning
- •Previous history of contrast allergy of adverse reactions (Gadolinium-containing agents)
Arms & Interventions
Healthy volunteers
Healthy volunteer subjects of similar age and gender to patient cohort.
Intervention: Prednisolone (Drug)
Cardiac Sarcoidosis
Patients with an established diagnosis of cardiac sarcoidosis.
Intervention: 18F-FDG (Other)
Cardiac Sarcoidosis
Patients with an established diagnosis of cardiac sarcoidosis.
Intervention: Prednisolone (Drug)
Healthy volunteers
Healthy volunteer subjects of similar age and gender to patient cohort.
Intervention: 18F-FDG (Other)
Outcomes
Primary Outcomes
Myocardial 18F-FDG uptake
Time Frame: Within 1 year
Quantification of myocardial PET tracer uptake after steroid therapy
Secondary Outcomes
No secondary outcomes reported